Biomarkers of gene expression: Growth factors and oncoproteins

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 807-816

  Brandt Rauf, Paul W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; Growth factors; Oncogene proteins; Serum biomarkers; Tumor suppressor gene proteins

Indexed keywords

BIOLOGICAL MARKER; GROWTH FACTOR; ONCOPROTEIN; PROTEIN P53;

CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; DISEASE CONTROL; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; TUMOR SUPPRESSOR GENE;

EID: 0030801959     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4807     Document Type: Conference Paper

References (125)

1. Leitzel K, Bryce W, Tomita J, Manderino G, Tribby I, Thomason A, Billingsley M, Podczaski E, Harvey H, Bartholomew M et al. Elevated plasma platelet-derived growth factor B-chain levels in cancer patients. Cancer Res 51:4149-4154 (1991).
2. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 20:11-17 (1991).
3. Niman HL, Thompson AMH, Yu A, Markham M, Willems JJ, Herwig KR, Habib NA, Wood CB, Houghten RA, Lerner RA. Anti-peptide antibodies detect oncogene-related proteins in urine. Proc Natl Acad Sci USA 82:7924-7928 (1985).
4. Wolf L, Mondhiry AL, Lynch J, Harvey H, Walker R, Langton B, Crebbin V, Porreca P, Lipton A. Plasma and ascites TGF-alpha levels in patients with solid tumors and hematologic disorders. Proc Am Assoc Cancer Res 31:A1333 (1990).
5. Katoh M, Inagaki H, Kurosawa-Ohsawa K, Katsuura M, Tanaka S. Detection of transforming growth factor alpha in human urine and plasma. Biochem Biophys Res Commun 167:1065-1072 (1990).
6. Chakrabarty S, Huang S, Moskal TL, Fritsche HA. Elevated serum levels of transforming growth factor-α in breast cancer patients. Cancer Lett 79:157-160 (1994).
7. Moskal TL, Huang S, Ellis LM, Fritsche HA, Chakrabarty S. Serum levels of transforming growth factor α in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev 4:127-131 (1995).
8. Partanen R, Koskinen H, Oksa P, Hemminki K, Carney W, Smith S, Brandt-Rauf PW. Serum oncoproteins in asbestosis patients. Clin Chem 41:1844-1847 (1995).
9. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, Tsushima H, Matsuzawa Y. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 83:676-679 (1992).
10. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y. Plasma transforming growth factor-b1 in patients with hepatocellular carcinoma. Cancer 73:2275-2279 (1994).
11. Murase T, Jirtle RL, McDonald GB. Transforming growth factor-β plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation. Blood 83:2383 (1994).
12. Klocker EI, Stenzl A, Cronauer MV, Draxl H, Hobisch A, Bartsch G. Quantitative determination of transforming growth factor-β in serum and urine in patients with bladder cancer and its expression in malignant and non-malignant primary epithelial cells. Proc Am Assoc Cancer Res 35:A261 (1994).
13. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RSH, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA et al. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1:129-136 (1995).
14. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimara T, Terada M. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180:386-392 (1991).
15. Fujimoto K, Ichimori Y, Yamaguchi H, Arai K, Futami T, Ozono S, Hirao Y, Kakizoe T, Terada M, Okajima E. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 86:182-186 (1995).
16. Ii M, Yoshida H, Aramaki Y, Masuya H, Hada T, Terada M, Hatanaka M, Ichimori Y. Improved enzyme immunoassay for human basic fibroblast growth factor using a new enhanced chemiluminescence system. Biochem Biophys Res Commun 193:540-545 (1993).
17. Kurobe M, Takei Y, Ezawa H, Hayashi K. Increased levels of basic fibroblast growth factor (bFGF) in sera of patients with malignant tumors. Horm Metab Res 25:395-396 (1993).
18. Takai Y, Kurobe M, Uchida A, Hayashi K. Serum concentrations of basic fibroblast growth factor in breast cancer. Clin Chem 40:1980-1981 (1994).
19. Li V, Yu C, Rupnick M, Allred E, Sallan S, Hayes DF, Folkman J. Serum from breast cancer patients contain proliferative activity for capillary endothelial cells which correlates with risk of mortality. Proc Annu Meet Am Soc Clin Oncol 12:A252 (1993).
20. Zimering MB, Katsumata N, Safo Y, Brandi ML, Aurbach GD, Marx SJ, Friesen HG. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. J Clin Endocrinol Metab 76:1182-1187 (1993).
21. Duensing S, Atzpodien J. Increased intracellular and plasma levels of task fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 85:1978-1980 (1995).
22. Sliutz G, Tempfer T, Obermair A, Reinthaller A, Gitsch G, Kainz C. Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 94:227-231 (1995).
23. Pawlikowski M, Cicslak D, Stepien H, Berner J, Rybinski K. Elevated blood serum levels of epidermal growth factor in some patients with gastric cancer. Endokrynol Pol 40:149-153 (1989).
24. Bhatavdekar JM, Patel DD, Vora H H, Balar DB. Circulating markers and growth factors as prognosticators in men with advanced tongue cancer. Tumor Biol 14: 55-58 (1993).
25. Shah NG, Bhatavdekar JM, Doctor SS, Suthar TP, Balar DB, Dave RS. Circulating EGF and IGF-I in patients with epithelial ovarian carcinoma. Neoplasma 41:241-243 (1994).
26. Ambs KE, Takahashi A, Hering F, Costa S, Huber PR. Epidermal growth factor in adenocarcinoma of the kidney. Urol Res 17:251-254 (1989).
27. Miyazaki S. Clinical study of the epidermal growth factor contents in urine, plasma and tissue from patients with urological disease. Hinyokika Kiyo 38:919-924 (1992).
28. Nedvidkova J, Nemec J, Stolba P, Varrejnova V, Bednar J. Epidermal growth factor (EGF) in serum of patients with differentiated carcinoma of thyroid. Neoplasma 39:11-14 (1992).
29. Peyrat JP, Bonneterre J, Vennin P, Louchez MM, Fournier C, Hecquet B, LeFebvre J, Demaille A. Insulin-like growth factor 1 (IGF1) plasma concentration in breast cancer patients. Proc Am Assoc Cancer Res 31:A295 (1990).
30. Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H, Sakai Y, Kato K, Katada N, Sugimoto Y, Takeichi M et al. Serum insulin-like growth factor II in chronic liver disease. Dig Dis Sci 34:338-342 (1989).
31. Macauley VM, Teale JD, Everard MJ, Joshi GP, Millar JL, Smith IE. Serum insulin-like growth factor I levels in patients with small cell lung cancer. Eur J Cancer Clin Oncol 24:1241-1242 (1988).
32. Hioki O, Watanabe A, Minemura M, Tsuchida T. Clinical significance of serum hepatocyte growth factor levels in liver diseases. J Med 24:35-46 (1993).
33. Nguyen M, Watanabe H, Budson AE, Richi JP, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356-362 (1994).
34. Yeh J, Yeh JC. Transforming growth factor α and human cancer. Biomed Pharmacother 43:651-660 (1989).
35. Hess JC, Sedghinasab M, Moe RE, Pearce LA, Tapper D. Growth factor profiles in breast cyst fluid identify women with increased breast cancer risk. Am J Surg 167:523-530 (1994).
36. Torrisi R, Zanardi S, Pensa F, Valenti G, DeFranchis V. Nicolo G, Barreca A, Minuto F, Boccardo F. Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. Breast Cancer Res Treat 33:219-224 (1995).
37. Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JMK, Kubo SH, Shumway SJ, Bolman RM, Bitterman PB. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 89:10385-10389 (1992).
38. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328:1592-1598 (1993).
39. Ford J, Smith S, Luo JC, Friedman-Jimenez G, Markowitz S, Garibaldi K, Niman H, Brandt-Rauf PW. Serum growth factors and oncoproteins in firefighters. Occup Med 42:39-42 (1992).
40. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 50:881-885 (1992).
41. Nilsson J, Volk-Joringe S, Svensson J, Landou C, DeFaire U, Hamsten A. Association between high levels of growth factors in plasma and progression of coronary atherosclerosis. J Int Med 232:397-404 (1992).
42. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyoshima K, Yamamoto T. in vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81:489-494 (1990).
43. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, McKenzie S, Hayes D, DeLellis R, Naber S, Wolfe H. Detection and quantitation of the human neu oncoprotein. Tumor Marker Oncol 6:53-72 (1991).
44. Narita T, Funahashi H, Satoh Y, Takagi H. c-erbB-2 protein in the sera of breast cancer patients. Gan To Kagaku Ryoho 19:909-911 (1992).
45. Narita T, Funahashi H, Satoh Y, Takagi H. c-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24:97-102 (1992)
46. Hosono M, Saga T, Sakahara H, Kobayashi H, Shirato M, Endo K, Yamamoto T, Akiyama T, Toyoshima K, Konishi J. Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. Jpn J Cancer Res 84:147-152 (1993).
47. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oeller M, Schauer A. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 119:249-252 (1993).
48. Pupa SM, Menard S, Morelli D, Pozzi B, DePalo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic clearage. Oncogene 8:2917-2923 (1993).
49. Kath R, Hoffken K, Metz K, Seeber S. Detection of the neu oncogene product in serum and tissue of patients with breast carcinoma. Proc Annu Meet Am Soc Clin Oncol 11:A180 (1992).
50. Kath R, Hoffken K, Orte C, Metz K, Scheulen ME, Hulskamp F, Seeber S. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 4:585-590 (1993).
51. Breuer B, DeVivo I, Luo JC, Smith S, Pincus MR, Tatum AH, Daucher J, Minick CR, Miller DG, Nowak EJ et al. ErbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prev 3:63-66 (1994).
52. Breuer B, Smith S, Osborne MP, Simons RM, Carney WP, Brandt-Rauf PW. ErbB-2 protein levels in healthy asymptomatic women. Biomarkers 1:141-143 (1996).
53. Ohuchi N, Abe N, Harada Y, Furuta A, Ikegaki H, Mori S. Serum levels of c-erbB-2 protein in patients with breast cancer: preliminary report. Nippon Geka Gakkai Zasshi 92:1530 (1991).
54. Yu FZ, Sugano K, Ohkura H, Mori S. Development of a sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma. Rinsho Byori 39:1087-1092 (1991).
55. Hayes DF, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Henderson IC. Elevated circulating HER-2/neu-related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 12:A35 (1993).
56. Estabrook A, Salinas RL, Chen J, Oster M, Yemul S, Leon JA. Soluble c-erbB-2 as a serum marker for advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 11:A131 (1993).
57. Hayden CL, Brower ST, Tamer PI. Circulating HER-2/neu levels in primary benign and malignant breast disease. Proc Annu Meet Am Soc Clin Oncol 11:A163 (1992).
58. Isola J, Kallioniemi OP, Mauceri J, Sampson E, Teramoto Y. Elevated preoperative serum levels of c-erbB-2 antigen in a small group of breast cancer patients with poor survival. Proc Am Assoc Cancer Res 33:A1512 (1992).
59. Montero S, Guzman C, Vegh I, Hitt R, Cortes-Funes H, Colomer R. Circulating neu oncogene product in metastatic breast cancer. Proc Am Assoc Cancer Res 35:A1338 (1994).
60. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen A-L. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncologica 34:499-504 (1995).
61. Pupa SM, Menard S, Andreda S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864-5866 (1993).
62. McKenzie SJ, Desombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (c-erbB-2) correlate with overexpression of p185 (neu) in human ovarian cancer. Cancer 71:3942-3946 (1993).
63. Wu JT, Astin ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 7:31-40 (1993).
64. Kaetsu T. Expression of c-erbB-2 protein in gastric carcinomas - correlation between immunohistochemical study and clinicopathological factors, DNA ploidy pattern and concentration of c-erbB-2 protein in serum. Nippon Shokakibyo Gakkai Zasshi 89:1147-1154 (1992).
65. Kaetsu T, Mogi Y, Kawamura M, Koike T, Ishizawa S, Fukuchi K, Takagi Y, Gomi K. Sensitive enzyme immunoassay by using chemiluminescence for the determination of serum c-erbB-2. Nippon Shokakibyo Gakkai Zasshi 88:1622 (1991).
66. Nakai M, Yonemura Y, Tsugawa K, Fushida Y, Yamaguchi A, Miwa K, Miyazaki I. Expression of soluble c-erbB-2 protein in serum of gastric cancer patients: preliminary report. Nippon Geka Gakkai Zasshi 93:337 (1992).
67. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 5:313-329 (1994).
68. Luo JC, Yu MW, Chen CJ, Santella RM, Carney WP, Brandt-Rauf PW. Serum c-erbB-2 oncopeptide in hepatocellular carcinogenesis. Med Sci Res 21:305-307 (1993).
69. Yu MW, Chen C-J, Luo J-C, Brandt-Rauf PW, Carney WP, Santella RM. Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Cancer Res 54:5106-5110 (1994).
70. Ohsaki T, Mitsudomi T, Oyama T, Kodate M, Nakanishi R, Shirakusa T. Serum levels of c-erbB-2 protein in patients with lung adenocarcinoma. Nippon Geka Gakkai Zasshi 94:320 (1993).
71. Brandt-Rauf PW, Luo JC, Carney WP, Smith S, DeVivo I, Milling C, Hemminki K, Koskinen H, Vaino H, Neugut AI. The detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int J Cancer 56:383-386 (1994).
72. Partanen R, Hemminki K, Koskinen H, Luo J-C, Carney WP, Brandt-Rauf PW. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 36:1324-1328 (1994).
73. Partanen R, Hemminki K, Brandt-Rauf PW, Jin C-G, Koskinen H. Serum levels of growth factor receptors, EGFR and neu in asbestosis patients: a follow-up study. Int J Oncol 4:1025-1028 (1994).
74. Braun A, Straif K, Presek P, Loeffler S, Woitowitz H-J. Detection of oncogene and tumor suppressor gene products in serum of former uranium miners for secondary prevention of radon-induced lung cancer. Proc Eur Conf Biomarkers Environ Toxicol 2:A6 (1995).
75. Witters LM, Curley EM, Kumar R, Chinchilli VM, Harvey JP, Crebbin V, Harvey HA, Lipton A. Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma. Clin Cancer Res 1:551-557 (1995).
76. Epelbaum R, Bartal AH, Amit R, Tugendhaft N, Shalitin C. Detection of p21 ras-related antigen in sera of cancer patients. Proc Annu Meet Am Soc Clin Oncol 8:A216 (1989).
77. Epelbaum R, Bartal AH, Rivkin M, Tugendhaft N, Shalitin C. Competitive ELISA for detection of native ras gene-related products in sera of cancer patients. J Clin Lab Anal 3:209-214 (1989).
78. Kakkanas A, Spandidos DA. Ras p21 oncoprotein in the sera of mice carrying experimentally induced tumor and in human cancer patients. in vivo 4:115-120 (1990).
79. Brandt-Rauf PW, Niman HL. Serum screening for oncogene proteins in workers exposed to PCBs. Br J Ind Med 45:689-693 (1988).
80. Brandt-Rauf PW, Smith S, Niman HL, Goldstein MD, Favata E. Serum oncogene proteins in hazardous-waste workers. J Soc Occup Med 39:141-143 (1989).
81. Brandt-Rauf PW, Smith S, Niman HL, Yohannan W, Hemminki K, Perera F, Santella R. Serum oncogene proteins in foundry workers. J Soc Occup Med 40:11-14 (1990).
82. Brandt-Rauf PW, Niman HL, Smith SJ. Correlation between serum oncogene protein expression and the development of neoplastic disease in a worker exposed to carcinogens. J Royal Soc Med 83:594-595 (1990).
83. Perera F, Fischman HK, Hemminki K, Brandt-Rauf PW, Niman HL, Smith S, Toporoff E, O'Dowd K, Tang MX, Tsai WY et al. Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy. Arch Toxicol 64:401-406 (1990).
84. Brandt-Rauf PW. Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis: the example of the ras oncogene encoded p21 protein. Int Arch Occup Environ Health 63:1-8 (1991).
85. Weissfeld JL, Larsen RD, Niman HL, Kuller LH. Evaluation of oncogene-related proteins in serum. Cancer Epidemiol Biomarkers Prev 3:57-62 (1994).
86. Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S, Niman H, Brandt-Rauf PW. Expression of p21 ras-related protein in the plasma and tissue of patients with adenomas and carcinomas of the colon. Biomarkers 1:29-33 (1996).
87. DeVivo I, Marion MJ, Smith SJ, Carney WP, Brandt-Rauf PW. Mutant c-Ki-ras p21 protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control 5:273-278 (1994).
88. Brandt-Rauf PW, Marion M-J, DeVivo I. Mutant p21 protein as a biomarker of chemical carcinogenesis in humans. In: Biomarkers and Occupational Health: Progress and Perspectives (Mendelsohn ML, Peeters JP, Normandy MJ, eds). Washington:Joseph Henry Press, 1995;163-173.
89. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao S-L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 3:67-71 (1994).
90. Takahashi M, Chen W, Byrd DR, Disis ML, Huseby ES, Qin H, McCahill L, Nelson H, Shimada H, Okuno K et al. Antibody to ras proteins in patients with colon cancer. Clin Cancer Res 1:1071-1077 (1995).
91. Scobbie AE, Anderson JB, Horwich A. Detection of activated ras p21 in urine samples associated with bladder and prostate cancer. J Occup Med 36:298-299 (1994).
92. Chan S, Evan G, Sikora K. The detection of c-myc oncogene product in patients with solid tumours. J Tumor Marker Oncol 1:93-99 (1986).
93. Chan S, Gabra H, Hill F, Evan G, Sikora K. A novel tumor marker related to the c-myc oncogene product. Mol Cell Probes 1:73-82 (1987).
94. DeVivo I, Breuer B, Smith S, Milling C, Pincus M, Tatum A, Niman H, Minick R, Osborne M, Miller D, Nowak E, Cody H, Brandt-Rauf PW. Detection of serum c-myc oncoprotein in cancer patients by immunoblot. Med Sci Res 21:345-347 (1993).
95. Ben-Mahrez K, Thierry D, Sorokine I, Danna-Muller A, Kohiyama M. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br J Cancer 57:529-534 (1988).
96. Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama K. Circulating antibodies against c-myc oncogene in sera of colorectal cancer patients. Int J Cancer 46:35-38 (1990).
97. Lafond RE, Eaton RB, Watt RA, Villee CA, Actor JK, Schur PH. Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians. Autoimmunity 13:215-224 (1992).
98. Sorokine I. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 47:665-669 (1991).
99. Virji MA, Rosendale B, Piper M, Carr B. Circulating levels of a mutant p53 protein in patients with hepatocellular carcinoma. Proc Am Assoc Cancer Res 33:A1508 (1992).
100. Rosanelli GP, Wirnsberger GH, Purstner P, Steindorfer P. DNA flowcytometry and immunohistochemical demonstration of mutant p53 protein versus TPS and mutant p53 protein serum levels in human breast cancer. Proc Am Assoc Cancer Res 34:A1353 (1993).
101. Micelli G, Donadeo A, Quaranta M. The p53 tumor suppressor gene - a preliminary clinical study in breast cancer patients. Cell Biophys 21:25-31 (1992).
102. Luo JC, Zehab R, Antilla S, Ridanpaa M, Husgafvel-Pursiainen K, Vainio H, Carney W, DeVivo I, Milling C, Brandt-Rauf PW. Detection of serum p53 protein in lung cancer patients. J Occup Med 36:155-160 (1994).
103. Fontanini G, Fiore L, Bigini D, Vignati S, Calvo S, Mussi A, Lucchi M, Angeletti CA, Merlo GR, Basolo F. Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 5:553-558 (1994).
104. Lehtinen T, Aine R, Kellokumpu-Lehtinen P, Hakala T, Lehtinen M. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma. Acta Oncol 32:779-781 (1993).
105. Trumper L, Jung W, Dahl G, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 5:93-96 (1994).
106. Greco C, Gandolfo GM, Mattei F, Gradilone A, Alvino S, Pastore LI, Casale V, Casole P, Grassi A, Cianciulli AM et al. Detection of c-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Res 14:1433-1440 (1994).
107. Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S. Carney WP, Brandt-Rauf PW. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 91:235-240 (1995).
108. Hemminki K, Partanen R, Koskinen H, Smith S, Carney W, Brandt-Rauf PW. The molecular epidemiology of oncoproteins: serum p53 protein in asbestosis patients. Chest 109:225-265 (1996).
109. Smith S, Marion M-J, Luo J-C, Brandt-Rauf PW. Mutant p53 protein as a biomarker of chemical carcinogenesis in humans. J Occup Environ Med 38:743 (1996).
110. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 8:1501-1509 (1993).
111. Crawrord LV, Piw DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408 (1982).
112. Fromentel CC, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 39:185-189 (1987).
113. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174 (1992).
114. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53 HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439-3442 (1992).
115. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marry M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-6384 (1992).
116. Labrecque S, Naor N, Thompson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468-3471 (1993).
117. Volkmann M, Muller M, Hoffmann W, Meyer M, Hagelstein J, Rath U, Kommerell B, Zentgraf H, Galle PR. The humoral immuno response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 18:559-565 (1993).
118. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Fromenrel CC, Preudhomme C, Fenaux P, Fournier G et al. Analysis of p53 antibodies in patients with various cancers defines B-cell epitopes of human p53: distribution on the primary structure and exposure on the protein surface. Cancer Res 53:5872-5876 (1993).
119. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant region in the p53 protein. Br J Cancer 69:809-816 (1994).
120. Angelopolou K, Diamandis EP. Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry. Cancer J 6:315-321 (1993).
121. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69:1115-1119 (1994).
122. Angelopolou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480-487 (1994).
123. Trivers GE, Cawley HL, Virna MG, DeBenedetti VMG, Hollstein M, Marion M-J, Bennett WP, Hoover ML, Prives CC, Tamburro CC et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87:1400-1407 (1995).
124. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, Vainio H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutations in the tumor tissue. Int J Cancer 64:176-181 (1995).
125. Sano T, Smith CL, Cantor CR. Immuno-PCR: a very sensitive antigen detection system using a DNA-antibody conjugate. Science 258:120-122 (1992).